{
    "ticker": "AGNCM",
    "name": "AbbVie Inc.",
    "description": "AbbVie Inc. is a global, research-driven biopharmaceutical company formed in 2013 when it was spun off from Abbott Laboratories. With a commitment to advancing health and improving lives, AbbVie focuses on developing innovative therapies to address some of the world's most serious health issues. The company's diverse portfolio includes treatments in immunology, oncology, neuroscience, and virology, with its flagship product, Humira, being one of the best-selling drugs worldwide for autoimmune diseases. AbbVie is also known for its efforts in research and development, investing heavily in discovering new medications to tackle unmet medical needs. The company has a strong pipeline of products, including therapies for conditions such as cancer, chronic pain, and psychiatric disorders. Through its partnerships and collaborations with other organizations, AbbVie aims to enhance access to its medicines and drive scientific innovation. With a focus on sustainability and corporate social responsibility, AbbVie is committed to creating a positive impact on the communities it serves, making it a leader in the biopharmaceutical industry.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "North Chicago, Illinois, USA",
    "founded": "2013",
    "website": "https://www.abbvie.com",
    "ceo": "Richard A. Gonzalez",
    "social_media": {
        "twitter": "https://twitter.com/abbvie",
        "linkedin": "https://www.linkedin.com/company/abbvie"
    },
    "investor_relations": "https://investors.abbvie.com",
    "key_executives": [
        {
            "name": "Richard A. Gonzalez",
            "position": "CEO"
        },
        {
            "name": "Robert A. Michael",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunology",
            "products": [
                "Humira",
                "Rinvoq",
                "Skyrizi"
            ]
        },
        {
            "category": "Oncology",
            "products": [
                "Imbruvica",
                "Venclexta"
            ]
        },
        {
            "category": "Neuroscience",
            "products": [
                "Duopa",
                "Vraylar"
            ]
        }
    ],
    "seo": {
        "meta_title": "AbbVie Inc. | Global Biopharmaceutical Company",
        "meta_description": "AbbVie Inc. is a global biopharmaceutical company focused on innovative therapies for challenging health issues. Discover our commitment to research, development, and improving lives.",
        "keywords": [
            "AbbVie",
            "Biopharmaceuticals",
            "Humira",
            "Immunology",
            "Oncology",
            "Neuroscience"
        ]
    },
    "faq": [
        {
            "question": "What is AbbVie known for?",
            "answer": "AbbVie is known for its innovative treatments in immunology, oncology, and neuroscience, with Humira as one of its flagship products."
        },
        {
            "question": "Who is the CEO of AbbVie?",
            "answer": "Richard A. Gonzalez is the CEO of AbbVie Inc."
        },
        {
            "question": "Where is AbbVie headquartered?",
            "answer": "AbbVie is headquartered in North Chicago, Illinois, USA."
        },
        {
            "question": "What are AbbVie's main products?",
            "answer": "AbbVie's main products include Humira, Rinvoq, Skyrizi, Imbruvica, and Venclexta."
        },
        {
            "question": "When was AbbVie founded?",
            "answer": "AbbVie was founded in 2013."
        }
    ],
    "competitors": [
        "PFE",
        "JNJ",
        "AMGN",
        "GILD"
    ],
    "related_stocks": [
        "MRK",
        "BMY",
        "AZN",
        "SNY"
    ]
}